FCSC Fibrocell Science Inc.

2.12
-0.12  -5%
Previous Close 2.24
Open 2.22
Price To Book 2.16
Market Cap 20687664
Shares 9,758,332
Volume 242,846
Short Ratio
Av. Daily Volume 1,170,051

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued December 18, 2009. Approved June 22, 2011.
Laviv
Wrinkles
Phase 2 endpoints not met - June 2016
azficel-T
Chronic Dysphonia
Phase 3 trial to commence 2Q 2019.
FCX-007
Recessive dystrophic epidermolysis bullosa
Phase 1/2 trial initiated August 2018.
FCX-013
Scleroderma

Latest News

  1. These 2 Biotech Stocks Are No Longer 'Off the Radar'
  2. Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
  3. ProQR Initiates Dosing in Phase II/III Eye Disorder Study
  4. Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises
  5. Fibrocell signs $135M deal to advance therapy for 'butterfly children'
  6. Fibrocell Announces Collaboration with Castle Creek Pharmaceuticals to Develop and Commercialize FCX-007 Gene Therapy
  7. Fibrocell Announces Board Member Christine St.Clare Honored by National Association of Corporate Directors
  8. Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007
  9. Fibrocell to Host Conference Call & Webcast for Full Year 2018 Financial Results and Recent Highlights on March 27, 2019
  10. Fibrocell to Present at 21st Annual BIO CEO & Investor Conference
  11. Fibrocell to Present at Phacilitate Leaders World 2019
  12. Fibrocell Receives $900,000 Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation
  13. What Kind Of Shareholders Own Fibrocell Science Inc (NASDAQ:FCSC)?
  14. Market Trends Toward New Normal in Fibrocell Science, Sears Hometown and Outlet Stores, Apellis Pharmaceuticals, Sigma Labs, Highpower International, and Nicholas Financial — Emerging Consolidated Expectations, Analyst Ratings
  15. Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights
  16. Intrexon (XON) Reports Narrower-Than-Expected Loss in Q3
  17. Fibrocell to Host Conference Call and Webcast on Tuesday, November 13, 2018 to Discuss Third Quarter 2018 Financial Results and Recent Highlights